{"id":"https://openalex.org/W1609976604","doi":"https://doi.org/10.1016/j.yrtph.2015.07.019","title":"Nonclinical safety testing of biopharmaceuticals \u2013 Addressing current challenges of these novel and emerging therapies","display_name":"Nonclinical safety testing of biopharmaceuticals \u2013 Addressing current challenges of these novel and emerging therapies","publication_year":2015,"publication_date":"2015-07-26","ids":{"openalex":"https://openalex.org/W1609976604","doi":"https://doi.org/10.1016/j.yrtph.2015.07.019","mag":"1609976604","pmid":"https://pubmed.ncbi.nlm.nih.gov/26219199"},"language":"en","primary_location":{"id":"doi:10.1016/j.yrtph.2015.07.019","doi":"https://doi.org/10.1016/j.yrtph.2015.07.019","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.yrtph.2015.07.019","pdf_url":null,"source":{"id":"https://openalex.org/S87719511","display_name":"Regulatory Toxicology and Pharmacology","issn_l":"0273-2300","issn":["0273-2300","1096-0295"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","medline","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory Toxicology and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031461430","display_name":"Frank R. Brennan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Frank R. Brennan","raw_affiliation_strings":["UCB Pharma, Slough, UK. Electronic address: frank.brennan@ucb.com","UCB Pharma, Slough, UK;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Slough, UK. Electronic address: frank.brennan@ucb.com","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"UCB Pharma, Slough, UK;","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074452979","display_name":"Andreas Baumann","orcid":"https://orcid.org/0000-0003-3034-4288","observed_orcids":["https://orcid.org/0000-0003-3034-4288"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andreas Baumann","raw_affiliation_strings":["Bayer Pharma AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayer Pharma AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046992582","display_name":"Guenter Blaich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128201","display_name":"AbbVie (Germany)","ror":"https://ror.org/03538jp08","country_code":"DE","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4210128201"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Guenter Blaich","raw_affiliation_strings":["Abbvie GmbH, Ludwigshafen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbvie GmbH, Ludwigshafen, Germany","institution_ids":["https://openalex.org/I4210128201"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053507694","display_name":"Lolke de Haan","orcid":"https://orcid.org/0000-0002-2201-293X","observed_orcids":["https://orcid.org/0000-0002-2201-293X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lolke de Haan","raw_affiliation_strings":["Medimmune LLC, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medimmune LLC, Cambridge, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046524736","display_name":"Rajni Fagg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rajni Fagg","raw_affiliation_strings":["Glaxo Smithkline Pharma, Stevenage, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Smithkline Pharma, Stevenage, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062808906","display_name":"Andrea Kie\u00dfling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Andrea Kiessling","raw_affiliation_strings":["Novartis Pharma, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002871553","display_name":"Sven Kronenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sven Kronenberg","raw_affiliation_strings":["Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014477849","display_name":"Mathias Locher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mathias Locher","raw_affiliation_strings":["Covagen, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covagen, Zurich, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085234028","display_name":"Mark Milton","orcid":"https://orcid.org/0009-0008-0972-0908","observed_orcids":["https://orcid.org/0009-0008-0972-0908"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Milton","raw_affiliation_strings":["Novartis Pharma, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma, Boston, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032746475","display_name":"Jay Tibbitts","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jay Tibbitts","raw_affiliation_strings":["UCB Pharma, Slough, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Slough, UK","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111459181","display_name":"Peter C. Ulrich","orcid":"https://orcid.org/0000-0001-6672-2223","observed_orcids":["https://orcid.org/0000-0001-6672-2223"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Peter Ulrich","raw_affiliation_strings":["Novartis Pharma, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077876000","display_name":"Lucinda R. Weir","orcid":"https://orcid.org/0000-0002-3563-6100","observed_orcids":["https://orcid.org/0000-0002-3563-6100"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lucinda Weir","raw_affiliation_strings":["Glaxo Smithkline Pharma, Stevenage, UK"],"raw_orcid":"https://orcid.org/0000-0002-3563-6100","affiliations":[{"raw_affiliation_string":"Glaxo Smithkline Pharma, Stevenage, UK","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5031461430"],"corresponding_institution_ids":["https://openalex.org/I4210134054"],"apc_list":{"value":4210,"currency":"USD","value_usd":4210},"apc_paid":null,"fwci":1.3066,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.7779219,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"73","issue":"1","first_page":"265","last_page":"275"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.538100004196167,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.538100004196167,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.3488999903202057,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12281","display_name":"Animal testing and alternatives","score":0.07010000199079514,"subfield":{"id":"https://openalex.org/subfields/3404","display_name":"Small Animals"},"field":{"id":"https://openalex.org/fields/34","display_name":"Veterinary"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nonclinical-safety-testing","display_name":"nonclinical safety testing","score":0.902999997138977},{"id":"https://openalex.org/keywords/biopharmaceuticals","display_name":"biopharmaceuticals","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-activation","display_name":"immune activation","score":0.7609999775886536},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.9940000176429749},{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.9670000076293945},{"id":"https://openalex.org/keywords/retroviral-vectors","display_name":"retroviral vectors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.6200000047683716},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.8029999732971191},{"id":"https://openalex.org/keywords/therapeutic-vaccines","display_name":"therapeutic vaccines","score":0.9909999966621399},{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9900000095367432},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.8849999904632568},{"id":"https://openalex.org/keywords/human-risk-assessment","display_name":"human risk assessment","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.713379979133606},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.7111454010009766},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5640701055526733},{"id":"https://openalex.org/C2994543053","wikidata":"https://www.wikidata.org/wiki/Q7239206","display_name":"Preclinical testing","level":2,"score":0.5093027353286743},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46942025423049927},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.4218595027923584},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.42113399505615234},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42087480425834656},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.41190004348754883},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4038141071796417},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.33110666275024414},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.32892972230911255},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2656314969062805},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2539407014846802},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2457987666130066},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.2392750382423401},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19408658146858215},{"id":"https://openalex.org/C19527891","wikidata":"https://www.wikidata.org/wiki/Q1120908","display_name":"Medical physics","level":1,"score":0.16942453384399414},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.15305909514427185},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.11354941129684448},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.08684268593788147}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012449","descriptor_name":"Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018675","descriptor_name":"Toxicity Tests","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059451","descriptor_name":"Biosimilar Pharmaceuticals","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.yrtph.2015.07.019","doi":"https://doi.org/10.1016/j.yrtph.2015.07.019","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.yrtph.2015.07.019","pdf_url":null,"source":{"id":"https://openalex.org/S87719511","display_name":"Regulatory Toxicology and Pharmacology","issn_l":"0273-2300","issn":["0273-2300","1096-0295"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","medline","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory Toxicology and Pharmacology","raw_type":"journal-article"},{"id":"pmid:26219199","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26219199","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regulatory toxicology and pharmacology : RTP","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9476000070571899,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W655182114","https://openalex.org/W1896894041","https://openalex.org/W1977046285","https://openalex.org/W1992928385","https://openalex.org/W1993639035","https://openalex.org/W1996815863","https://openalex.org/W2014275356","https://openalex.org/W2018944478","https://openalex.org/W2019164609","https://openalex.org/W2023749561","https://openalex.org/W2027005522","https://openalex.org/W2041573170","https://openalex.org/W2052771012","https://openalex.org/W2058832094","https://openalex.org/W2071631857","https://openalex.org/W2076675274","https://openalex.org/W2077812250","https://openalex.org/W2078607441","https://openalex.org/W2086286894","https://openalex.org/W2090810974","https://openalex.org/W2093039447","https://openalex.org/W2104088439","https://openalex.org/W2106698277","https://openalex.org/W2108079348","https://openalex.org/W2109699895","https://openalex.org/W2112802871","https://openalex.org/W2116193045","https://openalex.org/W2122038099","https://openalex.org/W2126607132","https://openalex.org/W2161447915","https://openalex.org/W2162676548","https://openalex.org/W2168819419"],"related_works":["https://openalex.org/W3002801484","https://openalex.org/W2883683525","https://openalex.org/W2512361481","https://openalex.org/W2093039447","https://openalex.org/W6980861988","https://openalex.org/W3130430787","https://openalex.org/W2794384167","https://openalex.org/W3178495098","https://openalex.org/W655906087","https://openalex.org/W2605623018"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}